First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.

ABSTRACT:

Background

Rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for acute and preventive migraine treatment in the United States and other countries. However, there is a lack of prospective real-world evidence for the use of rimegepant in Chinese migraine patients.

Methods

This was a single-arm, prospective, real-world study. While taking rimegepant to treat migraine attacks as needed, eligible participants were asked to record their pain intensity, functional ability, and accompanying symptoms for a single attack at predose and 0.5, 1, 2, 24, and 48 h postdose via a digital platform. Adverse events (AEs) during the rimegepant treatment period were recorded and analysed. The percentages of participants who experienced moderate

SUBMITTER: Yang Z 

PROVIDER: S-EPMC11438109 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature